Biotechnology in East Anglia


Goodwin's new office in Cambridge joins the ranking having recruited key partners and associates from Taylor Wessing LLP. It now has a deep bench of life sciences and technology specialists with extensive experience in advising some of the world's leading pharmaceutical companies. Their work encompasses complex global licensing and collaboration deals, contract disputes and venture capital financing. Tim Worden, who is 'great to have on your side of the table in a complex negotiation, given his knowledgeable and balanced negotiation style', David Mardle and Malcolm Bates are the lead partners. Associate Talitha Shkopiak moved firms with them.

Other key lawyers:

Talitha Shkopiak


We have only worked with Tim Worden in real detail. Tim has been a true adviser to our business on recent matters. He rolled his sleeves up in a manner which helped us get real comfort about an important in-licensing deal providing us pragmatic, timely and valuable advice. He is really easy to work with, was well regarded by the organisation outside of legal and was great to have on our side of the table in a complex negotiation given his knowledgeable and balanced negotiation style.

Key clients

Oxford Biomedica plc

Avacta Life Sciences Limited

Work highlights

  • Acted for Avacta Life Sciences Limited in an agreement with Daewoong Pharmaceutical Co., Ltd. to establish a joint venture in South Korea, and to enter a collaboration and licence agreement for the joint venture to develop the next generation of cell and gene therapies targeting immune-mediated diseases.
  • Acted for Oxford Biomedica plc on the extension of its commercial supply agreement by five years to manufacture Lentiviral Vectors

Mills & Reeve LLP

The Cambridge office of Mills & Reeve LLP advises biotechnology companies on corporate and commercial transactions, patents and IP, privacy, regulation, compliance, HR, pensions, product liability, dispute management, tax, share options and real estate matters. It acts for numerous small and medium-sized companies, as well as for global organisations such as Alere and ALK Abello. James Fry leads the multi-disciplinary life science practice, in which corporate finance partner Zickie Lim and IP specialist Alasdair Poore play key roles.

Practice head(s):

James Fry

Other key lawyers:

Zickie Lim; Alasdair Poore

Key clients

ALK Abello

Diurnal Group

Sphere Fluidics


Calypso Biotech

Kidney Research UK

Wellcome Sanger Institute

Aberystwyth University

University of Exeter

O2H Ventures

IQ Capital Fund II LP


ECO Animal Health

Atlantic Healthcare

L. D. Collins & Co.

MAP Biopharma

National Institute for Biological Standards and Control

Francis Crick Institute

Start Codon

Cobra Biologics

Alentis Therapeutics

Bit Bio

Work highlights

  • Advising the Sanger Institute on strategic research collaborations with industry partners.
  • Supporting Danish global pharma group ALK Abello in UK product compliance matters.
  • Advising AIM-listed pharma company Diurnal Group on a full-service basis across a range of commercial and supply chain transactions, regulatory matters and corporate fundraisings.

Penningtons Manches Cooper LLP

Penningtons Manches Cooper LLP has a cross-office biotechnology practice with a significant presence in Cambridge, where commercial IP specialist Rachel Bradley is the lead partner. Her in-house experience at a large pharmaceutical company is a major advantage in the firm's work on commercial agreements for biotechnology companies, which includes complex collaboration agreements. The firm frequently acts for  funders and universities in spinouts from academic research groups. Employment partner Hilary Aldred and corporate partner Ross McNaughton, who works in Cambridge and San Francisco, also play key roles.

Practice head(s):

Rachel Bradley

Other key lawyers:

Hilary Aldred; Ross McNaughton


The team did all it could to make the transaction go as smoothly and as quickly as possible. In addition, they were able to recommend other specialists to us and invited us to a useful meeting to investigate setting up in the US. All useful for a fast growing SME.

Rachel Bradley was very helpful and attentive and ensured her team met our needs. She also recommended other specialists to us and linked us up with the team at the JP Morgan Conference in San Francisco, which was very useful.

Key clients

The Company of Biologists Limited

Cytocell Limited

Wren Therapeutics Limited

Royal National Orthopaedic Hospital

Eternans Limited

Metrion Biosciences

Abcam PLC

King’s Commercialisation Institute

Atopix Therapeutics

Work highlights

  • Advising Chalante, an animal health drug discovery company in relation to material transfer agreements and confidentiality agreements with global pharmaceutical companies.
  • Regularly advising Wren Therapeutics Limited on IP and commercial matters, including protection of the company’s IP through consultancy agreements, sponsored research agreements and material transfer agreements.
  • Advising King’s Commercialisation Institute (part of King’s College London) on a manufacturing agreement for the production of GMP product with a King’s spin out company.

Taylor Wessing LLP

Life sciences and technology firm Taylor Wessing LLP saw key partners moved to Goodwin in 2019, but it retains significant expertise in its Cambridge office. Its team includes lawyers with experience gained with AstraZeneca, Mylan, Gilead, Roche and the Alan Turing Institute. In the biotechnology sector, they handle commercial arrangements, global licensing, complex collaboration deals, and contract disputes. Newly promoted partners Tasmina Goraya and Colin McCall, who splits his time between London and Cambridge, now lead the life sciences practice.

Practice head(s):

Tasmina Goraya;  Colin McCall

Key clients


Ellipses Pharma

Freeline Therapeutics

F-star Biotechnology

Oxford BioMedica





Rosa Biotech

Work highlights

  • Advised Black Belt Therapeutics Limited on a non-cash investment from Praxis Biotech LLC. In exchange for a stake in Black Belt, Praxis provided as consideration a number of pharmaceutical compounds/programs for Black Belt to use in developing their fledgling oncology business, following their recent spin-out from Tusk Therapeutics as part of its acquisition by Roche.
  • Represented Apotex Inc in the sale of its commercial operations in five European countries. This €74m deal, as reported in the press, includes a portfolio of over 200 generics, more than 80 over-the-counter (OTC) products, and an additional pipeline of over 20 products which are expected to be launched over the next two years.
  • Advised Ellipses Pharma, a global drug development company, on the negotiation and drafting of an exclusive worldwide licence agreement with NewLink Genetics for the development of and rights to commercialise NLG207 (formerly CRLX101) and CRLX-301.